EVIDENCE PROFILE · METABOLIC HEALTH

5-Amino-1MQ

In Plain English: 5-Amino-1MQ blocks an enzyme called NNMT, which is involved in cellular metabolism. Early laboratory and animal research suggests metabolic effects, but benefits and safety in humans remain unproven.

5-Amino-1MQ is technically a small molecule rather than a peptide. It is included in the Peptide Index because it is frequently discussed alongside metabolic and body-composition compounds.

Human Evidence○○○○○No established clinical efficacy evidence

The GapVERY WIDECommunity claims exceed human data

U.S. Regulatory StatusNot FDA approvedNo established medical indication or dose

01 / WHAT IT IS

Why NNMT matters.

5-Amino-1MQ is studied as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that processes nicotinamide and participates in cellular methylation and metabolic pathways.

Experimental studies have explored whether NNMT inhibition can influence fat-cell biology, energy metabolism and body composition. These mechanistic findings do not establish weight loss, muscle gain or longevity benefits in people.

02 / EVIDENCE CHECK

Promising biology. Unproven outcomes.

Preclinical signal

Cell and animal research supports interest in NNMT as a metabolic target. Effects seen in these models may not translate to humans.

Human evidence

There is no established body of controlled human trials demonstrating that 5-Amino-1MQ safely reduces body fat, improves metabolic health or builds muscle.

What the evidence does not mean: Blocking an enzyme in a laboratory does not prove that using a compound is safe, effective or beneficial in everyday human settings.

03 / COMMUNITY PULSE

What people are actually reporting.

Public biohacking discussions commonly frame 5-Amino-1MQ around fat loss, body recomposition, metabolic efficiency and combinations with other compounds. These are reported goals and claims, not verified treatment outcomes.

Reports can be confounded by concurrent diet changes, training, other drugs, uncertain product identity and selective posting. No reliable response rate or typical effect size can be inferred from them.

04 / COMMUNITY PROTOCOL SIGNAL

What the community discusses—not a protocol to follow.

Common discussion themes

Community conversations discuss repeated-use schedules, short cycles, different administration routes and pairing with weight-management compounds. The published human evidence does not validate any of these practices.

Dose, frequency and duration

No established human dose, route, frequency or cycle length exists. We have not independently verified a representative, source-backed numerical community range, so this profile does not present one as a consensus.

What people hope to notice

Users commonly discuss changes in body composition, weight and perceived energy. These reports do not distinguish drug effects from lifestyle changes, placebo effects or other interventions.

Protocol signal ≠ clinical guidance. Unregulated products may have uncertain identity, purity and exposure; long-term safety and drug-interaction risks are poorly characterized.

05 / SAFETY & REGULATORY

Unknowns matter.

5-Amino-1MQ is not FDA-approved for fat loss, metabolic health or any other indication. Human adverse-event rates, long-term effects, drug interactions and safe exposure limits have not been established.

Its relationship to nicotinamide metabolism does not mean that it is interchangeable with NAD+, NAD+ precursors or established metabolic medicines.

06 / RESEARCH STARTING POINTS

Follow the evidence.

Neelakantan et al. (2018) — selective NNMT inhibition and weight changes in diet-induced obese mice ↗

NNMT inhibition and metabolic dysfunction in obese mice (2024) — body composition, glucose and liver findings ↗

Combined NNMT inhibition and reduced-calorie diet in obese mice (2021) ↗

NNMT inhibition, diet and microbiome changes in obese mice (2022) ↗

Evidence note: these are preclinical studies in cells and/or rodents. They do not demonstrate efficacy or establish a safe dose in humans.

Check ClinicalTrials.gov for newly registered studies ↗

← Return to the Peptide Index

Editorial note: Educational information only; not dosing, sourcing or medical advice. Community reports are anecdotal and should not be mistaken for clinical evidence.

EVIDENCE VERIFICATION · OCTOBER 2026

5-Amino-1MQ: NNMT inhibition is not proven human fat loss

What the published evidence supports—and what it does not.

Preclinical mechanism5-Amino-1MQ is discussed as an inhibitor of nicotinamide N-methyltransferase (NNMT). Laboratory and animal findings are hypothesis-generating.

Human gapThere is no established human clinical efficacy or dosing regimen for 5-Amino-1MQ for fat loss, muscle preservation or metabolic health.

Community signalCommunity-reported amounts, routes and cycles are unverified and cannot substitute for clinical pharmacokinetic, safety and efficacy studies.

Regulatory status5-Amino-1MQ is not an FDA-approved medication. Long-term safety and human risk-benefit balance are unknown.

Research references

PubMed indexed NNMT and metabolic research (background, not a 5-Amino-1MQ human trial) ↗

This evidence check does not change the profile’s existing community-reporting content or constitute medical advice.